Illumina (ILMN) Gets Favroable Ruling in Complete Genomics (GNOM) Case
Tweet
Share
E-mailGet Alerts ILMN Hot Sheet
Join SI Premium – FREE
Illumina, Inc. (Nasdaq: ILMN) announced today that Magistrate Judge Elizabeth D. Laporte of the U.S. District Court for the Northern District of California issued a Claim Construction Order in the litigation brought by Illumina against Complete Genomics, Inc. (Nasdaq: GNOM).
Illumina has accused Complete Genomics of infringing U.S. Patent No. 6,306,597.
Judge Laporte’s February 8 Order provides the Court’s interpretation of the disputed terms in the patent asserted by Illumina. In its Order, the Court adopted constructions favorable to Illumina for the key terms in dispute. Illumina believes that the Court’s interpretations affirm the breadth of the patent and Illumina’s position that Complete Genomics infringes the patent.
Illumina has accused Complete Genomics of infringing U.S. Patent No. 6,306,597.
Judge Laporte’s February 8 Order provides the Court’s interpretation of the disputed terms in the patent asserted by Illumina. In its Order, the Court adopted constructions favorable to Illumina for the key terms in dispute. Illumina believes that the Court’s interpretations affirm the breadth of the patent and Illumina’s position that Complete Genomics infringes the patent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Quantum Cyber rejects short-seller's offer to halt reports if lawsuit dropped
- LiveRamp shrinks board to six directors after resignation
- Getty Realty discloses separation terms for departing accounting officer
Create E-mail Alert Related Categories
Corporate News, LitigationSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
